Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Welcomes the Inclusion of OFEV ® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Research